IDYA241220C20000
- 0.00
- 0.000.00%
IDEAYA Biosciences Newsroom
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Stephens Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $51
IDEAYA Biosciences Analyst Ratings
Ideaya Biosciences Initiated With an Overweight at Stephens
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
IDEAYA Biosciences: Strategic Initiatives and Growth Potential Reinforce Buy Rating
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $64
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
IDEAYA Biosciences Analyst Ratings
BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Promising Developments and Strong Financial Position Drive IDEAYA Biosciences Buy Rating
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
Oppenheimer Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $53
IDEAYA Biosciences Price Target Maintained With a $53.00/Share by Oppenheimer
IDEAYA Biosciences Analyst Ratings
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65